Efficacy of RCI001 as a Therapeutic Candidate in a Primary Sjögren Syndrome Mouse Model
Summary
Topical RCI001 demonstrated excellent therapeutic efficacy in a mouse model of primary Sjögren syndrome by inhibiting inflammation and oxidative stress. Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
| Authors | Kang H, Jung YH, Moon J, Ryu JS, Yoon CH, Kim YH, Kim MK, Kim DH |
|---|---|
| Journal | Cornea |
| Publication Date | 2025 Feb 1;44(2):226-233 |
| PubMed | 39288434 |
| PubMed Central | PMC11676593 |
| DOI | 10.1097/ico.0000000000003696 |